Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TGF-β2 silencing to target biliary-derived liver diseases.
Dropmann A, Dooley S, Dewidar B, Hammad S, Dediulia T, Werle J, Hartwig V, Ghafoory S, Woelfl S, Korhonen H, Janicot M, Wosikowski K, Itzel T, Teufel A, Schuppan D, Stojanovic A, Cerwenka A, Nittka S, Piiper A, Gaiser T, Beraza N, Milkiewicz M, Milkiewicz P, Brain JG, Jones DEJ, Weiss TS, Zanger UM, Ebert M, Meindl-Beinker NM. Dropmann A, et al. Among authors: janicot m. Gut. 2020 Sep;69(9):1677-1690. doi: 10.1136/gutjnl-2019-319091. Epub 2020 Jan 28. Gut. 2020. PMID: 31992593 Free PMC article.
TGF-β1 and TGF-β2 abundance in liver diseases of mice and men.
Dropmann A, Dediulia T, Breitkopf-Heinlein K, Korhonen H, Janicot M, Weber SN, Thomas M, Piiper A, Bertran E, Fabregat I, Abshagen K, Hess J, Angel P, Coulouarn C, Dooley S, Meindl-Beinker NM. Dropmann A, et al. Among authors: janicot m. Oncotarget. 2016 Apr 12;7(15):19499-518. doi: 10.18632/oncotarget.6967. Oncotarget. 2016. PMID: 26799667 Free PMC article.
TGF-ß isoforms in cancer: Immunohistochemical expression and Smad-pathway-activity-analysis in thirteen major tumor types with a critical appraisal of antibody specificity and immunohistochemistry assay validity.
Riemenschneider MJ, Hirblinger M, Vollmann-Zwerenz A, Hau P, Proescholdt MA, Jaschinski F, Rothhammer-Hampl T, Wosikowski K, Janicot M, Leo E. Riemenschneider MJ, et al. Among authors: janicot m. Oncotarget. 2015 Sep 29;6(29):26770-81. doi: 10.18632/oncotarget.5780. Oncotarget. 2015. PMID: 26450853 Free PMC article.
First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery.
Pfeiffer N, Voykov B, Renieri G, Bell K, Richter P, Weigel M, Thieme H, Wilhelm B, Lorenz K, Feindor M, Wosikowski K, Janicot M, Päckert D, Römmich R, Mala C, Fettes P, Leo E. Pfeiffer N, et al. Among authors: janicot m. PLoS One. 2017 Nov 30;12(11):e0188899. doi: 10.1371/journal.pone.0188899. eCollection 2017. PLoS One. 2017. PMID: 29190672 Free PMC article. Clinical Trial.
Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma.
Seystahl K, Papachristodoulou A, Burghardt I, Schneider H, Hasenbach K, Janicot M, Roth P, Weller M. Seystahl K, et al. Among authors: janicot m. Mol Cancer Ther. 2017 Jun;16(6):1177-1186. doi: 10.1158/1535-7163.MCT-16-0465. Epub 2017 Apr 4. Mol Cancer Ther. 2017. PMID: 28377490 Free article.
JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.
Arts J, King P, Mariën A, Floren W, Beliën A, Janssen L, Pilatte I, Roux B, Decrane L, Gilissen R, Hickson I, Vreys V, Cox E, Bol K, Talloen W, Goris I, Andries L, Du Jardin M, Janicot M, Page M, van Emelen K, Angibaud P. Arts J, et al. Among authors: janicot m. Clin Cancer Res. 2009 Nov 15;15(22):6841-51. doi: 10.1158/1078-0432.CCR-09-0547. Epub 2009 Oct 27. Clin Cancer Res. 2009. PMID: 19861438
61 results